Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week,
30 Million Euro Loan from the EIB for TB
VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa.
Hope for the elderly in the corona pandemic
First participants receive VPM1002 in a late-stage phase III clinical trial in Germany.
SARS-CoV-2 study kicks off in Germany
First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic.
Immune boost against the corona virus
In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus.
First volunteer enrolled
Vakzine Projekt Management GmbH: First volunteer enrolled in Phase II/III Study of SIIPL Tdap vaccine in Comparison with Boostrix® in Healthy Participants.
Modified TB vaccine as a therapy for bladder cancer
Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!
priMe AVAREF Meeting
The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24th of January 2020 in Nairobi, Kenya.
PhD award for Alexandra Hierweger
The VPM employee Alexandra Hierweger received the Uwe Koch-Gromus-PhD-Promotionspreis 2019 for her PhD thesis with the title ‘Influence of influenza A virus infections on the maternal immune system during pregnancy’. The ceremony took place on 6th of December 2019 at the University Medical Center Hamburg-Eppendorf.
PriMe Investigator Meeting
The priMe Investigator meeting has taken place from 27-28th of November 2019 in Dar es Salaam, Tanzania.